ClinicalTrials.gg
WithdrawnNCT04780893Updated Jan 16, 2024

Electrical Vestibular Nerve Stimulation (VeNS) as a Method of Sleep Management in People With PTSD

An interventional study of Modius Sleep in PTSD, Sleep Disturbance and Insomnia, sponsored by Neurovalens Ltd.. Withdrawn. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-16.

Sponsored by Neurovalens Ltd. · Not applicable, Interventional, and Supportive care

How we know

Why this study was withdrawn
New trial opportunity in the USA.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This double blind randomized controlled study will enroll 20 subjects and will be conducted remotely. The study will be randomized for an 8-week period with a 1:1 active to sham device allocation. Primary endpoint analysis will be performed at 4 weeks.

02

Conditions studied

03

In context

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Lead sponsor

Neurovalens Ltd. is the lead sponsor of 20 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Diagnosed PTSD by a medical practitioner
  3. Post-Traumatic Checklist (PCL-5) score of 31 or above
  4. Insomnia Severity Index (ISI) score of 15 or above
  5. Male or female, age ≥ 18 years and ≤ 80 years at the time of signing informed consent
  6. Ability and willingness to complete all study visits and procedures, including completion of mental health questionnaires
  7. Ability and willingness to adhere to 30 minutes usage of the device daily for the duration of the study
  8. No change to PTSD, mental health or insomnia medication within the past 3 months (regimen should be stable)
  9. Agreement not to change usage of prescription or over the counter PTSD, mental health or insomnia medications for the duration of the study
  10. Agreement not to undergo any significant lifestyle changes that may affect sleep (e.g., excessive exercise, sleep interventions etc.) for the duration of the study
  11. Agreement not to use sleep trackers (e.g., Fitbit) for the duration of the study
  12. Agreement not to travel across different time zones for the duration of the study
  13. Access to Wi-Fi (to enable the study app to upload usage data)
  14. Access to computer, laptop, iPad or tablet (to conduct remote study visits and complete study questionnaires remotely)
  15. Willing to download and use Zoom (to conduct remote study visits)

Exclusion criteria

Exclusion criteria:

  1. History of skin breakdown, eczema, or other dermatological condition (e.g., psoriasis) affecting the skin behind the ears
  2. Previous diagnosis of infection or AIDS (HIV is known to cause vestibular neuropathy which would prevent VeNS from working)
  3. Use of beta-blockers within 1 month of starting the study
  4. A history of stroke or severe head injury as defined by a head injury that required a craniotomy or endotracheal intubation (in case this damaged the neurological pathways involved in vestibular stimulation)
  5. Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.)
  6. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using an adequate method
  7. Diagnosis of epilepsy
  8. Diagnosis of active migraines
  9. Previous use of Modius device
  10. Participation in other research studies sponsored by Neurovalens
  11. Participation in any other sleep or PTSD studies
  12. Not fluent in English language
  13. Have a member of the same household who is currently participating in this study
  14. Failure to agree to use of device daily during study participation
  15. History of vestibular dysfunction or other inner ear disease
  16. Any other medical condition, or medication use, that in the opinion of the PI is likely to make the subject to VeNS.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Active VeNS

    Device: Modius Sleep

  • Sham comparator
    Sham VeNS

    Device: Modius Sleep

Interventions

  • DeviceModius Sleep

    The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index (ISI) score

    To evaluate the effect of the Modius Sleep device, relative to control group on participants with insomnia. ISI is a self-report rating scale assessing the severity of insomnia symptoms (range 0-28) with higher scores indicating a more severe insomnia.

    Time frame: 4 weeks

Secondary outcomes

  1. PCL-5 Score

    To evaluate the effect of the Modius Sleep device, relative to control group, on the symptoms of PTSD, quantified by change in the PCL-5 Score.

    Time frame: 4 weeks

  2. SF-36 Score

    To evaluate the effect of the Modius Sleep device, relative to control group, on quality of life, quantified by change in the SF-36 Score.

    Time frame: 4 weeks

  3. Generalised Anxiety Disorder (GAD-7) Scores

    To evaluate the effect of the Modius Sleep device, relative to control group, on anxiety, quantified by change in the GAD-7 score. GAD-7 is a self-report rating scale assessing the severity of anxiety (range 0-21), with higher score indicating more severe anxiety.

    Time frame: 4 weeks

  4. Prescription reduction

    To evaluate the effect of the Modius Sleep device, relative to control group, on prescription reduction, quantified by change in medication.

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Data will be transferred in an encrypted PDF format. Trial staff will be given direction on how to share the trial data and given access to one specific section of a controlled cloud service which is controlled via role based access. Once they have authenticated with the service and the service verifies that they have the correct role to access the system they will be directed to a single webpage within the application where they will be able to upload the encrypted PDF. This PDF is generated on the fly and is therefore not stored in another location that could become compromised. Generating the PDF on the fly means that the source data is extracted from the database, processed and delivered in the context of a single request. These data will be transferred for each subject when they complete participation in the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2022; primary completion for Apr 2022, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Mar 4, 2021
StartEst.
Feb 1, 2022
Primary completionEst.
Apr 2022
CompletionEst.
Apr 2022
Last update
Jan 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04780893
Lead sponsor
Neurovalens Ltd.
Collaborators
Clinical Trial Mentors
Responsible party
Sponsor
First posted
Mar 4, 2021
Start date
Feb 1, 2022 (estimated)
Primary completion
Apr 2022 (estimated)
Completion
Apr 2022 (estimated)
Last update
Jan 16, 2024

Study contacts

David Wilson, MD
principal investigator · Clinical Trial Mentors

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion